This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic (MDT) Launches Telescope Guide Extension Catheter
by Zacks Equity Research
The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.
ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI
by Zacks Equity Research
ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Varian Medical Installs ProBeam at Research Hub in Singapore
by Zacks Equity Research
Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.
Medtronic to Acquire Titan Spine for Spine Portfolio Boost
by Zacks Equity Research
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
by Zacks Equity Research
ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
by Zacks Equity Research
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Medtronic's (MDT) EV ICD Pilot Study Results Encourage
by Zacks Equity Research
The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) has been gaining investor confidence on robust performance.
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows
by Zacks Equity Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.
Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.
OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates
by Zacks Equity Research
Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.
Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.
Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.
McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.